Product Images Pirfenidone

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 8 images provide visual information about the product associated with Pirfenidone NDC 69097-988 by Cipla Usa Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1 - pirfenidone figure1

Figure 1 - pirfenidone figure1

The text is a table showing the percentage of patients who experienced either a decrease or increase in %FVC (forced vital capacity) after taking Pirfenidone or a placebo over the course of 52 weeks. It is not available whether Pirfenidone or a placebo is more effective.*

Figure 2 - pirfenidone figure2

Figure 2 - pirfenidone figure2

The text describes the mean change in FVC (Forced Vital Capacity) in milliliters over a period of weeks after using Piferidone drug compared to Placebo. However, due to the lack of context and formatting issues, the information provided is difficult to interpret.*

Figure 3 - pirfenidone figure3

Figure 3 - pirfenidone figure3

This is a statistical table showing the percentage of patients alive in a clinical trial comparing the drug Pirferidone against a placebo. The table includes the number of patients in each group, hazard ratios, and confidence intervals. The survival rate of patients taking Pirferidone is higher than that of the placebo group.*

267 mg - pirfenidone pdp 1

267 mg - pirfenidone pdp 1

This is a description of a medication called Pirfenidone, which comes in tablet form. Each film-coated tablet contains 267mg of Pirfenidone. The medication is available via prescription only, with dosage information provided in the package insert. It is recommended to store between 15°C-30°C (59°F-86°F). The medication is manufactured by Cipla USA, Inc. and ScieGen Pharmaceuticals, Inc. respectively.*

267 mg - pirfenidone pdp 2

267 mg - pirfenidone pdp 2

This is a prescription medication called Pirfenidone that comes in the form of tablets. Each film-coated tablet contains 267 mg of Pirfenidone. The usual dosage should be found in the package insert. It should be stored at room temperature between 15° and 30°C (59° to 86°F). It will be harmful to children and must be kept out of their reach. Cipla USA, Inc. produces it and ScieGen Pharmaceuticals, Inc. manufactures it in Hauppauge, NY.*

801 mg - pirfenidone pdp 5

801 mg - pirfenidone pdp 5

This is a description of a medication with the NDC number 69097-98805. The medication is available only by prescription and each film-coated tablet contains 801 mg of pirfenidone. The usual dosage information can be found in the package insert. The tablets should be stored at 25°C (77°F), with excursions permitted up to 15° to 30°C (59° to 86°F) as per USP controlled room temperature guidelines. The manufacturer's address is ScieGen Pharmaceuticals, Inc. and the medication comes in a bottle of 90 tablets. The has also included an unintelligible number at the end, possibly as a result of a scanning error.*

801 mg - pirfenidone pdp 6

801 mg - pirfenidone pdp 6

This is a prescription medicine that comes in the form of a film-coated tablet. Each tablet contains 801 mg of pirfenidone, which is used to treat idiopathic pulmonary fibrosis. The usual dosage information can be found in the package insert. The medicine should be stored at a temperature between 25°C and 30°C. The tablets are manufactured by ScieGen Pharmaceuticals for Cipla USA Inc. and come in a bottle of 270 tablets. This medication should be kept out of reach of children. Full prescribing information is available for P I rfen I d 0 n e.*

pirfenidone - pirfenidone structure

pirfenidone - pirfenidone structure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.